State-of-the-art management of renal cell carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 37, Issue 5, 2013, Pages 498-505

  Mourad, Waleed Fouad ^a,b   Dutcher, Janice ^a   Ennis, Ronald D ^a  

^a BETH ISRAEL MEDICAL CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Chemotherapy; Immunotherapy; Radiotherapy (RT); Renal cell carcinoma (RCC); Stereotactic body radiosurgery (SBRT); Targeted therapy

Indexed keywords

EID: 85028149428     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31825d5522     Document Type: Review

References (83)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;88:61-96.
2. Chow WH, Devesa SS, Warren JL, et al. Rising incidence of renal cell cancer in the United States. JAMA. 1999;281:1628-1631.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
4. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70:163-169.
5. Upton MP, Parker RA, Youmans A, et al. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother. 2005;28:488-495.
6. Takahashi M, Teh BT, Kanayam H-O. Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. J Med Invest. 2006;53:9-19.
7. McDermott DF, Ghebremichael MS, Signoretti S, et al. The high dose Aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (RCC). J Clin Oncol. 2010;28:15S. abstract 4514.
8. Shablak A, Sikand K, Shanks JH, et al. High dose interleukin-2 can produce a high rate of response and durable remissions in appropriately selected patients with metastatic renal cancer. J Immunother. 2011;34:107-112.
9. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
10. Gill IS, Matin SF, Desai MM, et al. Comparative analysis of laparoscopic versus open partial nephrectomy for renal tumors in 200 patients. J Urol. 2003;170:64-68.
11. Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass: a meta-analysis. Cancer. 2008;113:2671-2680.
12. Touijer K, Jacqmin D, Kavoussi LR, et al. The expanding role of partial nephrectomy: a critical analysis of indications, results, and complications. European Urol. 2010;57:214-222.
13. Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet. 2001;358:966-970.
14. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659.
15. Deschavanne PJ, Fertil B. A review of human cell radiosensitivity in vitro. Int J Radiat Oncol Biol Phys. 1996;34:251-266.
16. Orton CG, Ellis F. A simplification in the use of the NSD concept in practical radiotherapy. Br J Radio1. 1973;46:529-537.
17. Onufrey V, Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys. 1985;11:2007-2009.
18. Halperin EC, Harisiadis L. The role of radiation therapy in the management of metastatic renal cell carcinoma. Cancer. 1983;51:614-617.
19. Walsh L, Stanfield JL, Cho L C, et al. Efficacy of ablative highdose-per fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;29:29.
20. Maor MH, Frias AE, Oswald MJ. Palliative radiotherapy for brain metastases in renal carcinoma. Cancer. 1988;62:1912-1917.
21. Wronski M, Maor MH, Davis BJ, et al. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys. 1997;37:753-759.
22. Cannady SB, Cavanaugh KA, Lee SY, et al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renal cell carcinoma: a retrospective study. Int J Radiat Oncol Biol Phys. 2004;58:253-258.
23. Rades D, Heisterkamp C, Schild SE. Do patients receiving wholebrain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose? Int J Radiat Oncol Biol Phys. 2010;78:398-403.
24. Goyal LK, Suh J, Reddy CA, et al. The role of whole brain radiotherapy and stereotactic radiosurgery on brain metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2000;47:P1007-P1012.
25. Hoshi S, Jokura H, Nakamura H, et al. Gamma-knife radiotherapy for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol. 2002;9:618-625.
26. Sheehan JP, Sun MH, Kondziolka D, et al. Radiosurgery inpatients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. JNeurosurg. 2003;98:342-349.
27. Noel G, Valery CA, Boisserie G, et al. Linac radiotherapy for brain metastasis of renal cell carcinoma. Urol Oncol. 2004;22:25-31.
28. Chang EL, Selek U, Hassenbusch SJ III, et al. Outcome variation among "Radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery. 2005;56:936-945; discussion 936-945.
29. Shuto T, Inomori S, Fujino H, et al. Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. J Neurosurg. 2006;105:555-560.
30. Powell JW, Chung CT, Shah HR, et al. Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J Neurosurg. 2008;109(suppl):122-128.
31. Sperduto PW, Chao ST, Sneed PK, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys. 2010;77:655-661.
32. Teh BS, Bloch C, Paulino AC, et al. The treatment of primary and metastatic renal cell carcinoma (RCC) with stereotactic body radiation therapy and stereotactic radiosurgery. JCO, Part I. 2006;24(18S):14572.
33. Di Biase SJ, Valicenti RK, Schultz D, et al. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol. 1997;158:746-749.
34. Lee J, Hodgson D, Chow E, et al. A phase II trial of palliative radiotherapy for metastatic renal cell carcinoma. Cancer. 2005;104:1894-1900.
35. Svedman C, Sandstrom P, Pisa P, et al. A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol. 2006;45:870-875.
36. Gerszten PC, Burton S, Ozhasoglu C, et al. Stereotactic radiosurgery for spinal metastases from renal cell carcinoma. J Neurosurg Spine. 2005;3:288-295.
37. Uchida M, Imaide Y, Sugimoto K, et al. Percutaneous cryosurgery for renal tumours. Br J Urol. 1995;75:132-136.
38. Gervais DA, Arellano RS, McGovern FJ, et al. Radiofrequency ablation of renal cell carcinoma: part 2, lessons learned with ablation of 100 tumors. Am J Roentgenol. 2005;185:72-80.
39. Park S, Anderson JK, Matsumoto ED, et al. Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol. 2006;20:569-573.
40. Atwell TD, Farrell MA, Leibovich BC, et al. Percutaneous renal cryoablation: experience treating 115 tumors. J Urol. 2008;179:2136-2140; discussion 2140-2141.
41. Zagoria RJ, Traver MA, Werle DM, et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. Am J Roentgenol. 2007;189:429-436.
42. Ji C, Li X, Zhang S, et al. Laparoscopic radiofrequency ablation of renal tumors: 32-month mean follow-up results of 106 patients. J Urol. 2011;77:798-802.
43. Ritchie RW, Leslie T, Phillips R, et al. Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up. BJU Int. 2010;106:1004-1009.
44. Ponsky LE, Crownover RL, Rosen MJ, et al. Initial evaluation of Cyberknife technology for extracorporeal renal tissue ablation. Urology. 2003;61:498-501.
45. Ponsky LE, Mahadevan A, Gill IS, et al. Renal radiotherapy: initial clinical experience with histological evaluation. Surg In. 2007;14:265-269.
46. Beitler JJ, Makara D, Silverman P, et al. Definitive, high-dose-perfraction, conformal, stereotactic external radiation for renal cell carcinoma. Am J Clin Oncol. 2004;27:646-648.
47. Wersall PJ, Blomgren H, Lax I, et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol. 2005;77:88-95.
48. Teh BS, Paulino AC, Lu HH, et al. Versatility of the Novalis system to deliver image-guided stereotactic body radiation therapy for various anatomical sites. Technol Cancer Res Treat. 2007;6:347-354.
49. Svedman C, Karlsson K, Rutkowska E, et al. Stereotactic body radiotherapy of primary and metastatic renal lesions for patients with only one functioning kidney. Acta Oncol. 2008;47:1578-1583.
50. Kaplan ID, Redrosa I, Martin C, et al. Results of a phase I dose escalation study of stereotactic radiosurgery for primary renal tumors. Int J Rad Biol Phys. 2010;78:s191.
51. Kim TH, Somerville PJ, Freeman CR. Unilateral radiation nephropathy-the long-term significance. Int J Radiat Oncol Biol Phys. 1984;10:2053-2059.
52. Willett CG, Tepper JE, Orlow EL, et al. Renal complications secondary to radiation treatment of upper abdominal malignancies. Int J Radiat Oncol Biol Phys. 1986;12:1601-1604.
53. Lo S, Fakiris A, Chang E, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7:44-54.
54. Klapper JA, Downey SG, Smith FO, et al. High dose interleukin-2 for the treatment of metastatic renal cell carcinoma: a retrospective analysis of response and survival of patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008;113:293-301.
55. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133-141.
56. Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003;21:3127-3132.
57. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2005;6:836-848.
58. Parton M, Gore M, Eisen T. Role of cytokines therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 2006;24:5584-5592.
59. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
60. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (Anti-CTLA4 Antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-830.
61. Keir ME, Francisco LM, Sharpe HA. PD-1 and its ligands in T-cell immunity. Curr Opin Innumol. 2007;19:309-314.
62. Thompson RH, Gillett MD, Cheveille JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 2004;101:17174-17179.
63. Brahmer JR, Topalian S, Wollner I, et al. Safety and activity of MDX-1106 (ONO-4538), an anti-PD-1 monoclonal antibody, in patients with selected refractory or relapsed malignancies. J Clin Oncol. 2008;26:3006.
64. Hallahan DE, Spriggs DR, Beckett MA, et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci USA. 1989;86:10104-10107.
65. Zhang JS, Nakatsugawa S, Niwa O, et al. Ionizing radiationinduced IL-1 alpha, IL-6 and GM-CSF production by human lung cancer cells. Chin Med J (Engl). 1994;107:653-657.
66. Reits EA, Hodge JW, Herberts CA, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med. 2006;203:1259-1271.
67. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516-7523.
68. Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589-595.
69. Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71:2488-2496.
70. Cowey CL, Hutson RE. VEGF pathway-directed therapies in renal carcinoma. In: Stadler WM, ed. Renal Cancer, Emerging Cancer Therapeutics. New York, NY: Demos Medical Publishing; 2011:115-136.
71. Kaelin WG Jr. The von-Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer. 2008;8:865-873.
72. Dutcher JP. mTOR pathway-directed agents in renal cell carcinoma. In: Stadler WM, ed. Renal Cancer, Emerging Cancer Therapeutics. New York, NY: Demos Medical Publishing; 2011:137-144.
73. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-434.
74. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-134.
75. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results of sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-3590.
76. Escudier B, Bellmunt J, Negrier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in pateints with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol. 2010;28:2144-2150.
77. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28:2137-2143.
78. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010;28:1061-1068.
79. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007;356:2271-2281.
80. Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116:4256-4265.
81. Bhargava P, Esteves B, Nosov DA, et al. Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol. 2009;27(15S):5032.
82. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treatment in patients with cytokine refractory metastatic renal cell cancer: a phase II study. Lancet Oncol. 2007;8:975-984.
83. Hussein M, Smith M, Sweeney C, et al. Cabozantinib (XL184) in metasatic castration-resistant prostate cancer (mCRPC) Results from a phase II randomized discontinuation trial. J Clin Oncol. 2011;29(15S):293s. (abstract 4516).